NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

$14.27
+0.67 (+4.93%)
(As of 11:00 AM ET)
Today's Range
$14.20
$14.92
50-Day Range
$13.60
$17.30
52-Week Range
$13.16
$21.95
Volume
374,919 shs
Average Volume
489,117 shs
Market Capitalization
$5.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.27

Bausch + Lomb MarketRank™ Stock Analysis

Analyst Rating
Hold
2.45 Rating Score
Upside/​Downside
41.7% Upside
$19.27 Price Target
Short Interest
Healthy
4.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.15mentions of Bausch + Lomb in the last 14 days
Based on 33 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
33.33%
From $0.66 to $0.88 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.61 out of 5 stars

Medical Sector

245th out of 904 stocks

Ophthalmic Goods Industry

3rd out of 7 stocks

BLCO stock logo

About Bausch + Lomb Stock (NYSE:BLCO)

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

BLCO Stock Price History

BLCO Stock News Headlines

Rich Dad Poor Dad Author Shocks Millions With 2024 Crash Warning
Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.
Bausch + Lomb (NYSE:BLCO) Price Target Cut to $15.00
Rich Dad Poor Dad Author Shocks Millions With 2024 Crash Warning
Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.
Bausch + Lomb Quarterly Loss Widens
Bausch + Lomb Q1 2024 Earnings Preview
Bausch + Lomb Corporation (BLCO)
See More Headlines
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2024
Today
5/06/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
N/A
Fax
N/A
Employees
13,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.45
High Stock Price Target
$25.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+34.8%
Consensus Rating
Hold
Rating Score (0-4)
2.45
Research Coverage
11 Analysts

Profitability

Net Income
$-260,000,000.00
Pretax Margin
-4.66%

Debt

Sales & Book Value

Annual Sales
$4.15 billion
Cash Flow
$2.01 per share
Book Value
$19.72 per share

Miscellaneous

Free Float
N/A
Market Cap
$5.03 billion
Optionable
Optionable
Beta
0.47
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Osama A. Eldessouky (Age 52)
    Executive VP & CFO
    Comp: $1.09M
  • Dr. Yehia Hashad M.D. (Age 57)
    Executive VP of Research & Development and Chief Medical officer
    Comp: $1.09M
  • Mr. Brenton L. Saunders J.D. (Age 54)
    CEO & Chairman
  • Mr. Alan Waterhouse CPFA (Age 64)
    MBA, Executive VP and Chief Supply Chain & Operations Officer
  • Mr. Frederick J. Munsch (Age 53)
    Senior VP, Controller & Chief Accounting Officer
  • Mr. A. Robert D. Bailey (Age 61)
    Executive VP & Chief Legal Officer
  • Mr. Jonathon L. Kellerman
    Chief Compliance Officer
  • T.J. Crawford
    Chief Communications Officer
  • Dr. Manisha A. Narasimhan Ph.D. (Age 47)
    Chief Corporate Development & Digital Officer
  • Ms. Asli Gevgilili
    Executive VP & Chief Human Resources Officer

BLCO Stock Analysis - Frequently Asked Questions

Should I buy or sell Bausch + Lomb stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BLCO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCO, but not buy additional shares or sell existing shares.
View BLCO analyst ratings
or view top-rated stocks.

What is Bausch + Lomb's stock price target for 2024?

11 equities research analysts have issued 1-year target prices for Bausch + Lomb's shares. Their BLCO share price targets range from $15.00 to $25.00. On average, they predict the company's share price to reach $19.27 in the next twelve months. This suggests a possible upside of 41.7% from the stock's current price.
View analysts price targets for BLCO
or view top-rated stocks among Wall Street analysts.

How have BLCO shares performed in 2024?

Bausch + Lomb's stock was trading at $17.06 at the beginning of the year. Since then, BLCO shares have decreased by 20.3% and is now trading at $13.60.
View the best growth stocks for 2024 here
.

Are investors shorting Bausch + Lomb?

Bausch + Lomb saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,630,000 shares, an increase of 8.7% from the March 31st total of 1,500,000 shares. Based on an average trading volume of 464,700 shares, the days-to-cover ratio is currently 3.5 days. Approximately 4.3% of the shares of the company are short sold.
View Bausch + Lomb's Short Interest
.

When is Bausch + Lomb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our BLCO earnings forecast
.

How were Bausch + Lomb's earnings last quarter?

Bausch + Lomb Co. (NYSE:BLCO) issued its quarterly earnings data on Wednesday, May, 1st. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.09 by $0.02. The company had revenue of $1.10 billion for the quarter, compared to analysts' expectations of $1.06 billion. Bausch + Lomb had a positive trailing twelve-month return on equity of 3.60% and a negative net margin of 7.81%. Bausch + Lomb's quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.10 EPS.

What ETF holds Bausch + Lomb's stock?

Ballast Small/Mid Cap ETF holds 159,288 shares of BLCO stock, representing 1.72% of its portfolio.

What guidance has Bausch + Lomb issued on next quarter's earnings?

Bausch + Lomb issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.6 billion-$4.7 billion, compared to the consensus revenue estimate of $6.4 billion.

When did Bausch + Lomb IPO?

Bausch + Lomb (BLCO) raised $788 million in an initial public offering on Friday, May 6th 2022. The company issued 35,000,000 shares at a price of $21.00-$24.00 per share.

Who are Bausch + Lomb's major shareholders?

Bausch + Lomb's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%), Renaissance Capital LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Bausch + Lomb?

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BLCO) was last updated on 5/6/2024 by MarketBeat.com Staff

From Our Partners